Communiqués Amarin Corporation plc

Actions

AMRN

US0231112063

Temps Différé Nasdaq Autres places de cotation 22:00:00 18/06/2024			Varia. 5j.	Varia. 1 janv.
0,7301 ^USD	-3,68%		-5,18%	-16,08%

12/06	Les actions européennes négociées aux États-Unis sous forme de certificats américains d'actions étrangères (ADR) sont en forte hausse mercredi matin.	MT
11/06	Les actions européennes négociées aux États-Unis et les American Depositary Receipts sont en forte baisse mardi.	MT

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Amarin Board of Directors Announces CEO Transition	04/06	GL
Amarin Board of Directors Announces CEO Transition	04/06	AQ
AMARIN RECEIVES NATIONAL REIMBURSEMENT FOR VAZKEPA IN GREECE AND ANNOUNCES EXCLUSIVE MARKETING AND COMMERCIALIZATION AGREEMENT WITH VIANEX S.A.	29/05	AQ
Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A.	28/05	GL
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference	06/05	GL
Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference	06/05	AQ
Amarin: Q1 Earnings Snapshot	01/05	AQ
Amarin Reports First Quarter 2024 Business Update and Financial Results	01/05	GL
Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event	24/04	GL
Amarin Announces Results of Annual General Meeting of Shareholders	22/04	GL
Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024	15/04	GL
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24	08/04	GL
New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	08/04	AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	06/04	AQ
New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups	06/04	GL
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe	03/04	GL
Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe	03/04	AQ
Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo	25/03	GL
Amarin: Q4 Earnings Snapshot	29/02	AQ
Amarin Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	29/02	GL

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Amarin Corporation plc

Actions

AMRN

US0231112063

Communiqués

Filtres